Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab Consolidation After Chemoradiation Therapy (CRT) for Patients With Limited Stage Small-Cell Lung Cancer in China: A Multicentre, Observational Study (DREAM)

NCT07161388 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07161388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07161388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab Consolidation After Chemoradiation Therapy (CRT) for Patients With Limited Stage Small-Cell Lung Cancer in China: A Multicentre, Observational Study (DREAM)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
November 17, 2025
Completion date
September 30, 2028
Enrollment
200 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

limited stage small-cell lung cancer